Brevifolin

Brevifolin is a xanthone compound that inhibits α-glucosidase enzyme with an IC50 of 323.46 μM, potentially affecting glucose metabolism. This bioactive compound also functions as an aryl hydrocarbon receptor (AhR) inhibitor in laboratory studies.

Origin & History

Brevifolin carboxylic acid is a natural bioactive compound from Polygonum capitatum, also known as smartweed. It belongs to the isocoumarins and derivatives class, featuring an isochromane core.

Historical & Cultural Context

There are no documented historical or traditional medicinal uses for brevifolin carboxylic acid or its source plant Polygonum capitatum. It is primarily noted as a phytochemical isolate.

Health Benefits

• Inhibits α-glucosidase, potentially impacting glucose metabolism (IC50: 323.46 μM) [in vitro evidence]. • Acts as an inhibitor of the aryl hydrocarbon receptor (AhR) [in vitro evidence]. • No human clinical benefits have been documented due to a lack of studies. • Benefits are theoretical based on enzyme inhibition observed in vitro. • Further research is required to substantiate health claims.

How It Works

Brevifolin inhibits α-glucosidase enzyme activity with an IC50 value of 323.46 μM, potentially slowing carbohydrate digestion and glucose absorption. The compound also acts as an antagonist of the aryl hydrocarbon receptor (AhR), which regulates xenobiotic metabolism and inflammatory responses. These dual mechanisms suggest potential roles in glucose homeostasis and cellular detoxification pathways.

Scientific Research

No human clinical trials or meta-analyses have been found for brevifolin carboxylic acid. The available data are limited to in vitro studies, with no PMIDs for human studies.

Clinical Summary

Currently, no human clinical trials have been conducted on brevifolin supplementation. Available evidence comes exclusively from in vitro laboratory studies examining enzyme inhibition and receptor binding activities. The α-glucosidase inhibition data shows moderate potency compared to pharmaceutical alternatives, but lacks validation in living systems. Clinical benefits remain theoretical and require human studies to establish safety, efficacy, and appropriate dosing protocols.

Nutritional Profile

Brevifolin is a pure isolated polyphenolic lactone compound (a coumarin derivative, specifically a dilactone of brevifolic acid), not a whole food or dietary ingredient, and therefore carries no conventional macronutrient or micronutrient profile. Molecular formula: C11H6O7; molecular weight: 254.16 g/mol. It is classified as an ellagitannin-related metabolite and belongs to the class of dehydroellagic acid derivatives found in plants such as Phyllanthus niruri, Euphorbia species, and Canarium species. As a pure bioactive compound, it contains no protein, fat, carbohydrates, fiber, vitamins, or dietary minerals in any nutritional sense. The sole nutritionally relevant characteristic is its bioactive phytochemical activity: demonstrated α-glucosidase inhibitory activity (IC50: 323.46 μM in vitro) and aryl hydrocarbon receptor (AhR) antagonism (in vitro). Bioavailability data in humans is absent; as a lactone polyphenol, compounds in this structural class typically exhibit limited oral bioavailability due to susceptibility to hydrolysis in the gastrointestinal tract, potential gut microbiome metabolism, and limited intestinal permeability, though specific pharmacokinetic data for brevifolin in humans has not been established. Concentration in source plants varies by species and extraction method; no standardized dietary concentration reference has been published.

Preparation & Dosage

No clinically studied dosage ranges are available due to the absence of human trials. In vitro studies used concentrations such as 10 mM in DMSO. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Resveratrol, Curcumin, Quercetin, Berberine, Green tea extract

Safety & Interactions

Safety data for brevifolin supplementation in humans is unavailable due to lack of clinical studies. Potential interactions with diabetes medications cannot be ruled out given the α-glucosidase inhibitory activity observed in laboratory settings. Pregnant and breastfeeding women should avoid brevifolin supplements due to insufficient safety data. The compound's effects on AhR signaling may theoretically influence drug metabolism, though specific interactions remain unknown.